Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio SALT LAKE CITY, Nov. 09, 2023 ...
Announcing an artificial intelligence (AI) drug discovery partnership with Nvidia earlier this month, Recursion co-founder and CEO Chris Gibson, PhD, spoke as much about dollars as he did about drugs ...
Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...
PHILADELPHIA - Recursion (NASDAQ: RXRX), a clinical stage TechBio company with a market capitalization of $2.27 billion, has entered into a licensing agreement with HealthVerity to utilize its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback